Following U.S. Stocks are among the “Most Active” Stocks in the course of recent trading session, Monday: Ceres Inc (NASDAQ:CERE), Microvision, Inc (NASDAQ:MVIS), Cytori Therapeutics Inc (NASDAQ:CYTX), Advaxis, Inc (NASDAQ:ADXS)
- Ceres Inc (NASDAQ:CERE), with shares skyrocketed 36.45% is now trading at $0.453. The Stock is active as 2.05M shares changed hands versus its average volume of 1.00M shares.
- Microvision, Inc (NASDAQ:MVIS), with shares raised 22.53% is now trading at $3.35, hitting new 52-week high of $3.39. The Stock is active as 5.36M shares changed hands versus its average volume of 467,478.00 shares.
- Cytori Therapeutics Inc (NASDAQ:CYTX) with shares enhanced 11.68% is now trading at $1.34. The Stock is active as 3.29M shares changed hands versus its average volume of 6.83M shares.
- Advaxis, Inc (NASDAQ:ADXS), with shares rose 9.99% is now trading at $13.65, hitting new 52-week high of $14.23. The Stock is active as 1.34M shares changed hands versus its average volume of 890,935.00 shares.
Latest NEWS regarding these Stocks are depicted underneath:
Ceres, Inc. (NASDAQ:CERE)
Today, Ceres, Inc. (CERE), an agricultural biotechnology corporation, and Brazilian energy corporation Raízen S.A., declared that they have signed a multi-year partnership contract to develop and produce sweet sorghum on an industrial scale. Sweet sorghum can be grown to complement existing feedstock supplies and extend the operating season of Brazilian sugarcane-to-ethanol mills.
Under the collaboration, the companies will each contribute in-kind services and resources and share in the proceed from the ethanol produced from Ceres’ sweet sorghum above certain levels. This season, Raízen has planted Ceres’ sweet sorghum evaluation in a single location and plans to expand to multiple mills in the seasons to come.
Ceres President and CEO Richard Hamilton said that the corporation is happy to be working more closely with Raízen, which has taken a leading role in adopting new agricultural and industrial technologies. “The ethanol industry in Brazil has a history of successfully competing against low-priced oil and we believe that sweet sorghum, which has lower production costs than sugarcane, can be further developed and scaled up as an integral part of the industry’s feedstock supply,” said Hamilton.
Raízen, a joint venture of Royal Dutch Shell and Cosan, has taken a keen interest in developing and scaling up sweet sorghum as a means to grow margins and raise supply for its sugar and ethanol facilities. The corporation has conducted field and industrial evaluations of Ceres’ sweet sorghum hybrids since 2011.
Raízen, a joint venture of Royal Dutch Shell and Cosan, is Brazil’s fifth largest corporation in terms of proceed and the nation’s leading producer of sugarcane ethanol. With 24 sugar and ethanol facilities, the corporation produces more than 2 billion liters of ethanol, 4.5 million tons of sugar and 900 MW of electricity from biomass each year.
Ceres, Inc. is an agricultural biotechnology corporation that develops and markets seeds to produce crops for markets that utilize plant biomass, counting biofuels, renewable electricity and livestock feed and forage. The corporation’s technology platforms, which can raise crop productivity, improve quality, reduce crop inputs and improve cultivation on marginal land, have broad application across multiple crops, counting food, feed, fiber and fuel crops. Ceres markets its seed products under its Blade brand.
Microvision Inc. (NASDAQ:MVIS)
Today, Microvision Inc. (MVIS), a leader in innovative ultra-miniature projection display technology, declared it has received orders totaling $14.5 million for components for its Fortune Global 100 customer.
MicroVision plans to start shipment of components for these orders in the second half of 2015 and anticipates fulfillment to continue into 2016. MicroVision and its Fortune Global 100 customer recently reached a licensing contract whereby MicroVision granted a non-exclusive license to its patented PicoP® display technology to the Fortune Global 100 corporation. The components MicroVision is selling to its customer are predictable to be incorporated into display modules the Fortune Global 100 has developed. MicroVision will also be entitled to royalty payments upon any sales by its customer of the display modules. MicroVision is presently fulfilling component orders received in the second half of 2014 for this same customer.
MicroVision, Inc. is engaged in the development of its proprietary PicoP display technology that can be used by its customers to create miniature laser display and imaging engines in the United States. MicroVision’s patented display technology assists OEMs break down display boundaries and offer improved visibility to mobile experiences.
Cytori Therapeutics, Inc. (NASDAQ:CYTX)
Cytori Therapeutics, Inc. (CYTX), declared its fourth quarter and year end 2014 business and financial results.
2014 Highlights:
2014 was a year of noteworthy restructuring and refocusing of clinical programs, expense administration, and sales and marketing activities and working to raise proceed opportunities through partnerships, and licensing our non-core activities. Below are some highlights from 2014 and the starting of 2015.
- Refocused strategy and corporate restructuring – May’ 14
- Published Phase I/II clinical data for scleroderma – Aug’ 14
- Received BARDA approval for a $12M contract option and affirmed an $8.3M conditional option to support thermal burn injury program – Aug’ 14
- Received FDA IDE approval for US knee osteoarthritis trial (ACT-OA trial) – Sept’ 14
- Extended principal payment deferral on our current debt obligation by 5 months – Oct’14
- Resolved ATHENA trial hold – Oct’ 14
- Received FDA IDE conditional approval for US scleroderma pivotal trial (STAR trial) – Dec’ 14
- Raised the August contract option with BARDA to $14M to accelerate thermal burn injury program-Dec’ 14
- Received FDA IDE full approval for US STAR trial– Jan’ 15
- Enrolled the first patient in US ACT-OA trial – Feb’ 15
- Received positive EMA (European Medicines Agency) opinion on orphan drug status for Cytori Cell Therapy (ECCS-50) – Feb’ 15
- Received FDA approval of STAR trial site expansion to 20 sites – Feb’ 15
- Expanded global patent portfolio to a total of 75 patents, with 45 applications pending.
“The corporation, quite deliberately, pivoted in 2014 in terms of clinical and operating focus,” said Dr. Marc H. Hedrick, President and CEO of Cytori Therapeutics. “We have initiated two new clinical programs and moved them into late stage trials here in the U.S. In parallel, we have reduced our operating burn substantially by focusing only on those activities that are best positioned in our view of improving shareholder value in the nearer term.”
Cytori Therapeutics, Inc., a cell therapy corporation, develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions.
Advaxis, Inc. (NASDAQ:ADXS)
Today, Advaxis, Inc. (ADXS), a clinical-stage cancer immunotherapy corporation, presented preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in 10 patients with HPV-associated locally advanced anal cancer indicating that all patients who have accomplished treatment in the study have had a complete response with no evidence of recurrence to date (follow-up ranging from 0.5 — 24 months). The preliminary data also show that the investigational immunotherapy was well tolerated by the treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which comprise chills/rigors, fever and nausea.
The data were highlighted in an oral presentation by Kimberly Perez, M.D., Assistant Professor of Medicine at the Alpert Medical School, Brown University, during the recent International Anal Neoplasia Society (IANS) Scientific Meeting 2015, in Atlanta, Georgia.
According to the American Cancer Society, most squamous cell anal cancers seem to be linked to infection by the human papilloma virus (HPV), the same virus that causes cervical cancer. In fact, women with a history of cervical cancer (or pre-cancer) have an raised risk of anal cancer. Anal cancer is fairly rare — much less ordinary than cancer of the colon or rectum. About 7,210 new cases will be diagnosed and about 950 people are predictable to die of anal cancer in the United States during 2014.
Advaxis, Inc., a clinical stage biotechnology corporation, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
